| Followers | 1131 |
| Posts | 32852 |
| Boards Moderated | 3 |
| Alias Born | 01/11/2016 |
Tuesday, August 06, 2024 1:38:30 AM
Now, I think I know who you are, you have a brother (Andrew) that lives in Cali that you hate so much, you actually despise him and you have changed your alias three times since then. How else would you know Dina Greeves. Go figure, the mind of a trader who has false hopes. You need deliverance and a lot of help.
Recent KTTA News
- Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer • GlobeNewswire Inc. • 05/04/2026 11:01:00 AM
- Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) • GlobeNewswire Inc. • 04/20/2026 11:01:00 AM
- Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity • GlobeNewswire Inc. • 04/01/2026 11:01:00 AM
- Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/17/2026 12:01:00 PM
- Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines • GlobeNewswire Inc. • 01/13/2026 12:01:00 PM
- Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock • GlobeNewswire Inc. • 12/02/2025 12:00:00 PM
- Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock • GlobeNewswire Inc. • 11/28/2025 02:20:00 PM
- Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS • GlobeNewswire Inc. • 11/25/2025 12:00:00 PM
- Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data • GlobeNewswire Inc. • 11/24/2025 12:00:00 PM
- Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients • GlobeNewswire Inc. • 11/21/2025 05:35:00 PM
- Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study • GlobeNewswire Inc. • 11/20/2025 09:01:00 PM
- Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients • GlobeNewswire Inc. • 11/04/2025 12:03:00 PM
- Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients • GlobeNewswire Inc. • 09/16/2025 11:03:00 AM
- Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients • GlobeNewswire Inc. • 09/08/2025 11:01:00 AM
- Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 08/29/2025 12:39:00 PM
- Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 08/28/2025 11:02:00 AM
- Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients • GlobeNewswire Inc. • 07/31/2025 11:01:00 AM
- Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board • GlobeNewswire Inc. • 06/11/2025 11:02:00 AM
- Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 • GlobeNewswire Inc. • 06/02/2025 12:02:00 PM
